Inhibrx Q2 net loss $36.7M; cash $219.5M post $100M Oxford loan; ozekibart PDUFA Apr 2027

Inhibrx Biosciences, Inc.

2026-Q2 EPS reported -$4.49

Net loss $36.7M ($2.34/share) vs $28.7M ($1.85/share) in Q2 2025; no revenue vs $1.3M prior year.
Cash $133.3M at June 30; $219.5M as of Aug 6 after $100M funded from $325M Oxford loan amendment.
FDA accepted BLA for ozekibart in chondrosarcoma; PDUFA date April 14, 2027.
INBRX-106 PFS data from Phase 2 HNSCC trial expected Q3 2026; new CRC cohorts initiated.
R&D $23.9M, G&A $8.3M, up from $22.3M and $6.4M respectively.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.